MATINAS BIOPHARMA HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1675 USD | -1.47% |
|
-1.82% | -22.53% |
Presentation Operator MessageOperator (Operator)Hello and welcome to the Matinas BioPharma fou...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.1675
USD
Average target price
0.8667
USD
Spread / Average Target
+417.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.53% | 42.01M | |
| +9.58% | 115B | |
| +12.41% | 107B | |
| -3.41% | 21.6B | |
| -12.38% | 22.31B | |
| -6.59% | 19.19B | |
| -3.35% | 18.23B | |
| -38.57% | 17.62B | |
| +7.51% | 14.26B | |
| +35.67% | 12.37B |
- Stock Market
- Equities
- MTNB Stock
- News Matinas BioPharma Holdings, Inc.
- Transcript : Matinas BioPharma Holdings, Inc., Q4 2021 Earnings Call, Mar 08, 2022
